A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Abstract The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to provide information about current and futur...
Saved in:
| Main Authors: | Melissa L. Johnson, Jessica J. Lin, Adrienne Boire, Melin J. Khandekar, Helena A. Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-12-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-024-00315-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01) -
Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01) -
Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis
by: Yuqin Long, et al.
Published: (2025-01-01) -
Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC
by: Rodryg Ramlau, et al.
Published: (2025-08-01) -
De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)